Abstract
Bipolar disorders (BD) are characterized by cognitive impairment during the euthymic phase, to which treatments can contribute. The anticholinergic properties of medications, i.e., the ability of a treatment to inhibit cholinergic receptors, are associated with cognitive impairment in elderly patients and people with schizophrenia but this association has not been well characterized in individuals with remitted bipolar disorders. Moreover, the validity of anticholinergic burden scales designed to assess the anticholinergic load of medications has been scarcely tested in bipolar disorders. We aimed to test the concurrent validity of several scales by assessing their associations with objective cognitive impairment and subjective anticholinergic side-effects in BD. We hypothesized that the scale is valid if its association with cognitive impairment or self-reported anticholinergic side-effects is significant. A sample of 2,031 individuals with euthymic bipolar disorders was evaluated with a neuropsychological battery to identify cognitive impairment. Two scales among 27 were significantly positively associated with cognitive impairment in multiple logistic regressions, whereas chlorpromazine equivalents, lorazepam equivalents, the number of antipsychotics, or the number of treatments were not. The two scales significantly correlated with worse performance in processing speed and verbal memory. In addition, 14 scales showed good concurrent validity to assess self-reported peripheral anticholinergic side-effects and 13 were valid for evaluating self-reported central anticholinergic side-effects. Thus, we identified valid scales to monitor the anticholinergic burden in BD, which may be useful in assessing iatrogenic cognitive impairment in studies investigating cognition in BD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by a grant from the Centre Hospitalier de Versailles (Bourse Registre 2019), the Fondation FondaMental, Creteil, France, and the Investissements d'Avenir Programs managed by the ANR under references ANR-11-IDEX-0004-02 and ANR-10-COHO-10-01.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Comite de Protection des Personnes - Ile de France IX gave ethical approval for this work (refered documents are available upon request).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors